An experimental cancer drug appears to have cured all patients in a clinical trial in the United States. Dostarlimab is a monoclonal antibody that likely completely eliminated colorectal cancer in the patients involved in this trial.
In a clinical trial, all patients treated for non-metastatic rectal cancer with dostarlimab, an immunotherapy monoclonal antibody produced by a biotech acquired by the giant GSK, are in remission six to twenty-five months after treatment. With much better tolerance than the standard treatment based on radiochemotherapy and surgery.
“Dr. Luis A. Diaz Jr., an author of a paper published Sunday in the NEJM describing the results, said he knew of no other study in which a treatment completely obliterated a cancer in every patient: ‘I believe this is the first time this has happened in the history of cancer.’” https://t.co/0ckpGY5tS0
— Heather Jameson (@hjamesdc) June 6, 2022
“I believe this is the first time this has happened in the history of cancer.” Doctor Luis A. Diaz Jr., of Memorial Sloan Kettering Cancer Center does not hide his enthusiasm after the results obtained during this clinical trial.
Along with other doctors, he has just published an article in the leading medical journal New England Journal of Medicine on a clinical trial conducted among a dozen patients with colorectal cancer in the United States.
Read also :
Major cancer discovery: new antibody blocks tumor growth and metastasis, hope for new treatment
These patients with rectal cancer had to face exhausting treatments – chemotherapy, radiotherapy, with fears of surgery with serious consequences.
A great medical first concerning the treatment of colorectal cancer
But the results were amazing. The cancer disappeared in each patient.
The American study, presented on Sunday June 5 at the ASCO Cancer Congress (in Chicago, USA) and published the same day in the New England Journal of Medicine, brings new hope to many patients.
Read also :
What is eleucerobin, this molecule which could become a remedy against cancer?
The patients concerned were affected by specific tumours. If the results are confirmed, this will revolutionize the treatment of this subgroup of colorectal cancers. Especially since this anomaly of the tumor is found more frequently in colorectal cancers, but it also exists in other cancers. Hence the hope that this treatment will also be used to treat other types of cancer.